| No images? Click here  Thursday, 29 May 2025 SITUATION REPORT Multi-country outbreak of mpox, External situation report #53 - 29 May 2025 This is the 53rd situation report for the multi-country outbreak of mpox, which provides details on the global epidemiological situation for mpox with data as of 30 April 2025, including an update on the epidemiological situation for mpox in Africa, with data as of 18 May 2025, updates on imported cases of mpox due to clade I MPXV as of 21 May 2025 and the operational response updates as of 23 May 2025. Highlights • Ten countries in Africa have reported community transmission of mpox due to clade Ib monkeypox virus (MPXV) in the past six weeks. • The Democratic Republic of the Congo continues to report the highest number of confirmed mpox cases in Africa in 2025, with important information and reporting gaps emerging partly due to a reduction in testing and confirmation capacity. Clades Ia and Ib MPXV continue to circulate in the country. • A downward trend in confirmed cases has been reported in Uganda in recent weeks. However, the country continues to experience a large outbreak, reporting close to 200 new confirmed cases per week. • Burundi continues to observe fewer than 50 new confirmed cases per week, down from over 200 confirmed cases per week at the peak of the outbreak. • Sierra Leone continues to report a surge in the number of confirmed mpox cases observed over the past six weeks, with over 600 new confirmed cases reported during the most recent week, highlighting the rising transmission in the country. Currently available data indicate that the outbreak is largely occurring among young adults in urban contexts, concentrated in and around Freetown. Prior to this surge, only clade IIb MPXV had been detected, but efforts are underway to carry out genomic sequencing analysis for more recent samples. A WHO mission is underway to bolster the outbreak response. • Australia has reported its first case of mpox due to clade Ib MPXV, linked to travel to Thailand. Thailand has only reported travel-related cases of mpox due to clade Ib MPXV so far. • This report provides an overview of mpox vaccination in countries in the African Region, where to date more than 720 000 doses of MVA-BN vaccines have been administered in seven countries. Of all doses, 81% have been administered in the Democratic Republic of the Congo, where microplanning is ongoing to optimize use of the limited vaccine supply with targeted vaccination strategies.  Media contacts:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
0 Comments